Compare JILL & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JILL | GALT |
|---|---|---|
| Founded | 1959 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.7M | 199.2M |
| IPO Year | 2017 | 2008 |
| Metric | JILL | GALT |
|---|---|---|
| Price | $12.31 | $2.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $17.00 | $8.50 |
| AVG Volume (30 Days) | 49.8K | ★ 277.6K |
| Earning Date | 06-10-2026 | 05-15-2026 |
| Dividend Yield | ★ 2.42% | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | ★ 1.82 | N/A |
| Revenue | ★ $596,549,000.00 | N/A |
| Revenue This Year | $2.65 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.73 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.41 | $1.22 |
| 52 Week High | $18.80 | $7.13 |
| Indicator | JILL | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 48.26 | 56.58 |
| Support Level | $12.02 | $2.10 |
| Resistance Level | $12.71 | $2.60 |
| Average True Range (ATR) | 0.60 | 0.18 |
| MACD | 0.04 | 0.05 |
| Stochastic Oscillator | 41.86 | 77.70 |
J.Jill Inc is a national lifestyle brand that provides apparel, footwear, and accessories. The company's products are marketed under the J.Jill brand name and sold through its two channels: its e-commerce platform and catalog (Direct) and its retail stores (Retail). J.Jill caters to a distinctive set of women, typically forty-five years and older, offering them various apparel products, footwear, and accessories, comprising shirts, dresses, tops and tees, sweaters, pants and jeans, jewelry, bags, belts, shoes, scarves, etc. The company's operating segments consist of its Retail channels, which derive maximum revenue, and Direct channels. Geographically, the majority of its revenue is derived from the United States.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.